Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines (DPD côlon)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by ICO Paul Papin.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
ICO Paul Papin
ClinicalTrials.gov Identifier:
NCT01547923
First received: February 28, 2012
Last updated: March 5, 2012
Last verified: March 2012

February 28, 2012
March 5, 2012
June 2008
December 2012   (final data collection date for primary outcome measure)
Number and nature of grade IV toxicity. [ Time Frame: Up to 4 weeks. ] [ Designated as safety issue: Yes ]
The percentage of severe toxicity (grade IV) will be analyzed in each arm. We expect a reduction of the early, severe, grade IV acute side-effects from 3% to 0.6% in the detected group with adapted doses.
Same as current
Complete list of historical versions of study NCT01547923 on ClinicalTrials.gov Archive Site
  • Number of grade III-IV toxic events. [ Time Frame: Up to 6 months. ] [ Designated as safety issue: Yes ]
    We expect a reduction of the number of grade III-IV toxic events, whenever they occur, from 25% to 5% in the detected group with adapted doses.
  • Mortality rate. [ Time Frame: up to 6 months. ] [ Designated as safety issue: Yes ]
    The current mortality rate of 3 per thousand patients will be cut to 0 in the detected group with adapted doses.
  • Medical-financial study of pre-therapeutic screening. [ Time Frame: Up to 6 months. ] [ Designated as safety issue: No ]
    We will carry out a comparison of the prevention costs and the costs related to treating patients with toxicity. Direct costs and indirect costs will be taken into account.
Same as current
Not Provided
Not Provided
 
Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines
The Medical-financial Evaluation of Pre-therapeutic Screening by a Joint Phenotypic-pharmacogenetic Approach for Metabolic Fluoropyrimidine Enzyme Deficiency in Terms of Serious Toxicity Risk Prevention : a Multicentric Case Study

The aim of this study is to demonstrate the medical and financial benefit of pre-therapeutic screening of DPD deficiency for predicting toxicity to fluoropyrimidines.

The fluoropyrimidines, of which 5-Fluorouracil is the most important, represent a family of medication that is used in particular in cancerology. They are molecules widely used in cancerology since they can be found in nearly 45% of chemotherapy protocols and in the treatment of about 50% of cancers (colorectum, oesophagus, stomach, breast, upper digestive and respiratory tracts). They are not only used in metastatic situations but also more and more in adjuvant situations, in other words for patients treated for a localised tumour, presenting a risk of relapse. A severe toxic risk cannot be tolerated in these conditions, and the doctor should assure the maximum level of safety for his patients. These medicines are the cause of 3% of grade IV toxicity from the first or second administration, and for 0.3% of deaths. To this one can add on a total of 20 to 25% grade III-IV toxic events.

Anticancer treatment is mostly administered by body size and in the best of cases after a few basic biological examinations such as a haemogram and renal status, without taking into consideration any individual particularities, whether genetic or epigenetic. Among potential toxicity risk factors one can find individual metabolic differences linked to genetic modifications of metabolism enzymes as well as differences in the chemical receptors and transporters.

For fluoropyrimidines, a polymorphism was found for the dihydropyrimidine dehydrogenase gene (DPD), a major catabolism enzyme. A deficit of this enzyme is a major counter-indication for the use of these medicines.

Early determination of DPD status would allow identification of patients at risk and would thus help in subsequent dose adjustment or selection of other treatment modalities.

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Colorectal Cancer
  • Intravenous 5 Fluorouracile
  • Genetic: Blood sample for phenotypic and pharmacogenetic analysis.
    Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
  • Genetic: Blood sample for phenotypic and pharmacogenetic analysis.
    Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
  • Experimental: A : pre-therapeutic screening for DPD deficiency
    Prior to treatment by fluoropyrimidines,a DPD deficiency is identified by a joint phenotypic-pharmacogenetic approach.
    Intervention: Genetic: Blood sample for phenotypic and pharmacogenetic analysis.
  • B : no pretherapeutic research of DPD deficiency
    For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.
    Intervention: Genetic: Blood sample for phenotypic and pharmacogenetic analysis.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
2296
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • colorectal cancer, histologically confirmed, with all types included (including adjuvant cases), requiring treatment with intravenous 5-fluorouracil.
  • anterior chemotherapy authorised, with the exception of chemotherapy containing a derivate of 5-Fluorouracil
  • Age > or = 18 years
  • WHO Performance status < or = 2
  • Haematologic and hepatic parameters : neutrophils > or = 1000 /mm3, platelets > or = 100000/mm3, Total bilirubin < or = 2 x ULN, AST and ALT < or = 3 x ULN, APL < or = 5 x ULN
  • Complete initial assessment before first treatment administration for imaging and pharmacogenetic, within 15 days for biology, and within 7 days for clinical examination.
  • Signed written informed consent

Exclusion Criteria:

  • Prior chemotherapy with fluoropyrimidines
  • Symptomatic or uncontrolled ventral nervous system metastases
  • Psychiatric Disease disrupting the trial understanding and the enlightened and voluntary consent character
  • Patient who is pregnant or breast feeding
  • Woman not consenting to use adequate contraceptive precautions during the study
  • Patient who can not submit itself to the formal follow-up for psychological, social, family or geographical reasons
  • Significant serious pathology or any instable medical condition (cardiac pathology uncontrolled, myocardial infarction within 6 months before enrollment, systemic active uncontrolled infection)
  • any investigational agent within 4 weeks before enrollment
Both
18 Years and older
No
Contact: Virginie Berger, MD, PhD 33 2 41 35 27 34 virginie.berger@ico.unicancer.fr
Contact: Jessy Delaye, M Sc 33 2 41 35 29 31 jessy.delaye@ico.unicancer.fr
France
 
NCT01547923
CPP-380, 2008-000026-39
Yes
ICO Paul Papin
ICO Paul Papin
Not Provided
Principal Investigator: Olivier Capitain, MD, PhD ICO Paul Papin
ICO Paul Papin
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP